254 related articles for article (PubMed ID: 23527295)
1. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Chateau ML; Denton PW; Swanson MD; McGowan I; Garcia JV
PLoS One; 2013; 8(3):e60024. PubMed ID: 23527295
[TBL] [Abstract][Full Text] [Related]
2. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
[TBL] [Abstract][Full Text] [Related]
5. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
6. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
[TBL] [Abstract][Full Text] [Related]
7. No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Chopera DR; Mann JK; Mwimanzi P; Omarjee S; Kuang XT; Ndabambi N; Goodier S; Martin E; Naranbhai V; Karim SA; Karim QA; Brumme ZL; Ndung'u T; Williamson C; Brockman MA;
PLoS One; 2013; 8(8):e71758. PubMed ID: 24015191
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).
McGowan I; Hoesley C; Cranston RD; Andrew P; Janocko L; Dai JY; Carballo-Dieguez A; Ayudhya RK; Piper J; Hladik F; Mayer K
PLoS One; 2013; 8(4):e60147. PubMed ID: 23573238
[TBL] [Abstract][Full Text] [Related]
9. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
10. Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Li Q; Tso FY; Kang G; Lu W; Li Y; Fan W; Yuan Z; Destache CJ; Wood C
J Acquir Immune Defic Syndr; 2015 Aug; 69(5):519-27. PubMed ID: 26167617
[TBL] [Abstract][Full Text] [Related]
11. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
Rohan LC; Moncla BJ; Kunjara Na Ayudhya RP; Cost M; Huang Y; Gai F; Billitto N; Lynam JD; Pryke K; Graebing P; Hopkins N; Rooney JF; Friend D; Dezzutti CS
PLoS One; 2010 Feb; 5(2):e9310. PubMed ID: 20174579
[TBL] [Abstract][Full Text] [Related]
12. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
13. Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Chateau M; Swanson MD; Garcia JV
J Virol; 2013 Jan; 87(2):1274-7. PubMed ID: 23115295
[TBL] [Abstract][Full Text] [Related]
14. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
[TBL] [Abstract][Full Text] [Related]
15. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
[TBL] [Abstract][Full Text] [Related]
16. Rectal microbicide development.
McGowan I
Curr Opin HIV AIDS; 2012 Nov; 7(6):526-33. PubMed ID: 23032732
[TBL] [Abstract][Full Text] [Related]
17. A perspective on progress and gaps in HIV prevention science.
Kiser PF; Mesquita PM; Herold BC
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
[TBL] [Abstract][Full Text] [Related]
18. CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck.
Valley-Omar Z; Sibeko S; Anderson J; Goodier S; Werner L; Arney L; Naranbhai V; Treurnicht F; Abrahams MR; Bandawe G; Swanstrom R; Karim QA; Karim SS; Williamson C
J Infect Dis; 2012 Jul; 206(1):35-40. PubMed ID: 22551813
[TBL] [Abstract][Full Text] [Related]
19. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Veselinovic M; Yang KH; LeCureux J; Sykes C; Remling-Mulder L; Kashuba ADM; Akkina R
Virology; 2014 Sep; 464-465():253-263. PubMed ID: 25105490
[TBL] [Abstract][Full Text] [Related]
20. Reformulated tenofovir gel for use as a dual compartment microbicide.
Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
